Stopping MS drugs raised brain scan activity in stable MS

Credibility

Interest

Share:1 min read

Key Takeaway

People with stable MS who stopped first-line treatment had more new brain scan changes than those who continued.

What They Found

The trial compared stopping first-line MS treatment with continuing it. Eight of 45 people who stopped had new disease activity, compared with none of 44 who continued. Most new activity appeared on brain scans rather than as a flare-up. Two people who stopped treatment had a flare-up. Researchers ended the trial early because new disease activity exceeded a limit they had set.

Who Should Care and Why

The study included adults with MS that began with flare-ups. They had taken first-line treatment without a flare-up or major new brain scan changes for at least 5 years. The findings concern people considering whether to stop treatment after years of stable MS. Participants received care at 14 centers in the Netherlands. Their results show that stable MS can become active again after treatment stops.

Important Considerations

If you have stable MS, this trial does not show what would happen to you after stopping treatment. It included 89 people and ended early, after about 15 months of follow-up for the typical participant. The abstract does not report long-term disability outcomes.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News